title: Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
abstract: OBJECTIVE
  Patients with low-risk neutropenic fever as defined by the Multinational Association of Supportive Care in Cancer (MASCC) score might benefit from ambulatory treatment. Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting.
  
  
  METHODS
  Cancer patients with febrile neutropenia and a favorable MASCC score were randomized between oral moxifloxacin and intravenous ceftriaxone. All were fit for early hospital discharge. The global success rate was related to the efficacy of monotherapy, as well as to the success of ambulatory monitoring.
  
  
  RESULTS
  The trial was closed prematurely because of low accrual. Ninety-six patients were included (47 in the ceftriaxone arm and 49 in the moxifloxacin arm). A total of 65% were women, 30.2% had lymphoma, 34.4% had metastatic, and 35.4% had non-metastatic solid tumors. The success rates of home antibiotics were 73.9% and 79.2% for ceftriaxone and moxifloxacin, respectively. Seven patients were not discharged, and 14 required re-hospitalization. There were 17% of microbiologically documented infections that were, in most cases, susceptible to oral monotherapy.
  
  
  CONCLUSIONS
  These results suggest that MASCC is a valid and useful tool to select patients for ambulatory treatments and that oral moxifloxacin monotherapy is safe and effective for the outpatient treatment of cancer patients with low-risk neutropenic fever.
authors.affiliation: Centre Léon Bérard, 28 rue Laennec, Lyon, France. sebban@lyon.fnclcc.fr
authors.forename: Catherine
authors.initials: C
authors.lastname: Sebban
authors.forename: Sophie
authors.initials: S
authors.lastname: Dussart
authors.forename: Christine
authors.initials: C
authors.lastname: Fuhrmann
authors.forename: Hervé
authors.initials: H
authors.lastname: Ghesquieres
authors.forename: Isabelle
authors.initials: I
authors.lastname: Rodrigues
authors.forename: Lionel
authors.initials: L
authors.lastname: Geoffrois
authors.forename: Yves
authors.initials: Y
authors.lastname: Devaux
authors.forename: Laurence
authors.initials: L
authors.lastname: Lancry
authors.forename: Giselle
authors.initials: G
authors.lastname: Chvetzoff
authors.forename: Thomas
authors.initials: T
authors.lastname: Bachelot
authors.forename: Maria
authors.initials: M
authors.lastname: Chelghoum
authors.forename: Pierre
authors.initials: P
authors.lastname: Biron
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D024841:Fluoroquinolones; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D010351:Patient Discharge; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D002443:Ceftriaxone; D000077266:Moxifloxacin